Active Trials

These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.

Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.

Trial name A Randomized, Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)
Type of trial Phase III
Trial ID NCT 04348656
Health Canada Status Health Canada approved
Trial Status Open
Location
Ontario, Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Quebec, Saskatchewan, Northwest Territories, Nunavut, Yukon
Trial description

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

Study team
Donald Arnold
Dr. Donald Arnold
MD
McMaster University
Trial name ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease
Type of trial Phase III
Trial ID NCT 04329611
Health Canada Status Health Canada approved
Trial Status Open
Location
Alberta
Trial description

This study is for people with COVID-19 who are not hospitalized. The study compares hydroxychloroquine and placebo to see if people who take hydroxychloroquine are less likely to be hospitalized or die.

Study team
luanne metz
Dr. Luanne Metz
MD
University of Calgory
Michael Hill
Dr. Michael Hill
MD
University of Calgory
Trial name Assess the efficacy and safety of adjunctive humanized monoclonal Interleukin 6 receptor antibody Tocilizumab (TCZ) therapy to standard of care for the reduction of hyperinflammation related mortality in SARS-Cov2 positive patients
Type of trial Phase III
Trial ID NCT 04423042
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta
Trial description

This study is for people who are hospitalized with COVID-19. Study participants will receive either (1) tocilizumab with standard of care, or (2) standard of care, to see if tocilizumab prevents death and improves clinical symptoms.

Study team
Dr. Susanne Benseler
Dr. Susanne Benseler
MD, PhD
University of Calgary
Trial name CONCOR-KIDS: A randomized, multicentered, open-label Phase 2 clinical trial of the safety and efficacy of human Coronavirus-immune convalescent plasma for the treatment of COVID-19 disease in hospitalized children
Type of trial Phase II
Trial ID NCT04377568
Health Canada Status Health Canada approved
Trial Status Pending
Location
Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, Saskatchewan
Trial description

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

Study team
Dr. Julia Upton
Dr. Julia Upton
MD, MPH, Study Chair
Allergy and Immunology Department, The Hospital for Sick Children
Trial name Post-exposure Prophylaxis (PEP) or Preemptive Therapy for COVID-19: A Pragmatic Randomized Clinical Trial
Type of trial Phase III
Trial ID NCT 04308668
Health Canada Status Health Canada approved
Trial Status Open
Location
Quebec, Manitoba, Alberta, Ontario
Trial description

This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.

Study team
Todd C. Lee
Todd C. Lee, MD, MPH, FIDSA
Associate Professor in the Department of Medicine
McGill University
Ryan Zarychanski
Ryan Zarychanski
MD
University of Manitoba
Lauren E. Kelly
Lauren E. Kelly, PhD, MSc, CCRP
Clinical Trialist and Certified Clinical Research Professional with SoCRA
Organization
IIan Schwartz
IIan Schwartz
MD
University of Alberta
Emily McDonald
Emily McDonald, MD, MSc, FRCPC
Assistant Professor of Medicine
Organization
Dr. Zain Chagla
Dr. Zain Chagla
MD MSc FRCPC DTMH
McMaster University
Trial name Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO)
Type of trial Phase II
Trial ID NCT 04330690
Health Canada Status Health Canada approved
Trial Status Open
Location
Alberta, British Columbia, Ontario, Quebec
Trial description

This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.

Study team
Dr. Nelson Lee
Dr. Nelson Lee
MD
University of Alberta Hospital
Dr. Allison Mah
Dr. Allison Mah
MD
Vancouver General Hospital,
Dr. Natasha Press
Dr. Natasha Press
MD
St. Paul’s Hospital
Dr. Shane English
Dr. Shane English
MD
The Ottawa Hospital
Dr. Robert Fowler
Dr. Robert Fowler
MD
Sunnybrook Health Sciences Centre
Dr. Bryan Coburn
Dr. Bryan Coburn
MD
Toronto Western Hospital
Dr. Matthew Cheng
Dr. Matthew Cheng
MD
McGill University Health Centre-Glen Site Royal Victoria HospitalRecruiting
Dr. Alexis Turgeon
Dr. Alexis Turgeon
MD
CHU de Québec – Université Laval
Dr. Francois Lellouche
Dr. Francois Lellouche
MD
Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval
Dr. Daniel Ovekim
Dr. Daniel Ovekim
MD
Royal Jubilee Hospital
Dr. Anna Geagea
Dr. Anna Geagea
MD
North York General Hospital
Dr. Francois Lamontagne
Dr. Francois Lamontagne
MD
Centre Hospitalier de l'Université de Sherbrooke